Subgen AI AB (52Q0)
XFRA XFRA Primary 
XSTO Summary
52Q0 Chart
Subgen AI AB (52Q0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Subgen AI AB ever had a stock split?
Subgen AI AB Profile
| - Industry | - Sector | Mr. Lorenzo Serratosa Gallardo CEO | XFRA Exchange | SE0026820854 ISIN |
| Sweden Country | 251 Employees | - Last Dividend | 25 Nov 2025 Last Split | - IPO Date |
Overview
Subgen AI AB is a pioneering biotechnology company based in Lund, Sweden, which was established in 2019. Specializing in the development and commercialization of innovative diagnostic tests, Subgen AI focuses on monitoring and optimizing the dosage of biological drugs. The company's mission is to enhance personalized medicine through advanced diagnostic tools that facilitate tailored patient care within the pharmaceutical and healthcare industries. After rebranding from Magnasense AB in November 2025, Subgen AI has positioned itself as a crucial player in improving patient outcomes through its cutting-edge testing platforms, ensuring more accurate and effective therapeutic interventions.
Products and Services
- Veritope
Veritope is a state-of-the-art technology developed by Subgen AI to improve dosing accuracy for biological therapeutics. This platform allows healthcare professionals to monitor and adjust the dosage of medications based on patient-specific needs, ultimately enhancing treatment efficacy and minimizing adverse effects.
- MagniaReader
The MagniaReader platform is a versatile diagnostic tool designed for use in both research and veterinary settings. It streamlines the detection of infectious diseases and offers solutions for oral health monitoring. The platform leverages advanced technologies to provide rapid and accurate test results, supporting informed decision-making in various healthcare applications.
